Westport, CT, April 04, 2024 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Firm”), a medical know-how firm delivering unprecedented accuracy and precision to intracardiac sign visualization, introduced right this moment that it appointed Bridge Associates Worldwide Pharmaceutical Consulting (BAIPC) to advise on enterprise mannequin methods.
BAIPC will work to deploy a sequence of options to rework BioSig’s future course with further methods – together with operations, employees, methods, and processes. Various insurance policies and procedures can be evaluated and probably initiated to re-stabilize operational and monetary deficits and remodel them right into a restructured turnaround. BAIPC has an outreach help system with over 35 years’ expertise led by Anthony Amato. Mr. Amato is at present the CEO of InQuest Science and BAIPC.
About BioSig Applied sciences, Inc.
BioSig Technologies is a medical know-how firm targeted on deciphering the physique’s electrical alerts, beginning with coronary heart rhythms. By leveraging a primary of its variety mixture of {hardware} and software program, we ship unprecedented cardiac sign readability, ending the reliance on ‘blended alerts’ and ‘studying between the strains.’ Our platform know-how is addressing a few of healthcare’s largest challenges—saving time, saving prices, and saving lives.
The Firm’s product, the PURE EP Platform, an FDA 510(okay) cleared non-invasive class II gadget, gives superior, real-time sign visualization permitting physicians to carry out extremely focused cardiac ablation procedures with elevated procedural effectivity and efficacy.
An estimated, 14.4 million Individuals undergo from cardiac arrhythmias, and the cardiac ablation market in 2022 was valued at $3.5B in 2022 with an anticipated 13.5% progress fee.1
Ahead-Trying Statements
This press launch incorporates “forward-looking statements” throughout the that means of the Non-public Securities Litigation Reform Act of 1995. Such statements could also be preceded by the phrases “intends,” “could,” “will,” “plans,” “expects,” “anticipates,” “initiatives,” “predicts,” “estimates,” “goals,” “believes,” “hopes,” “potential” or comparable phrases. Ahead-looking statements should not ensures of future efficiency, are primarily based on sure assumptions, and are topic to varied recognized and unknown dangers and uncertainties, lots of that are past the Firm’s management, and can’t be predicted or quantified and consequently, precise outcomes could differ materially from these expressed or implied by such forward-looking statements. Such dangers and uncertainties embrace, with out limitation, dangers and uncertainties related to (i) BioSig’s potential to regain compliance with and meet the continued itemizing necessities of the Nasdaq Capital Market to keep up itemizing of its frequent inventory; (ii) our price discount plan and related workforce discount or different cost-saving measures not reaching the focused discount of money burn by 50%; (iii) the geographic, social, and financial affect of pandemics or worldwide well being points on BioSig’s potential to conduct its enterprise and lift capital sooner or later when wanted; (iv) BioSig’s lack of ability to fabricate its merchandise and product candidates on a business scale by itself, or in collaboration with third events; (v) difficulties in acquiring financing on commercially affordable phrases; (vi) adjustments within the measurement and nature of BioSig’s competitors; (vii) lack of a number of key executives or scientists; and (viii) difficulties in securing regulatory approval to market BioSig’s merchandise and product candidates. For a dialogue of different dangers and uncertainties, and different vital elements, any of which might trigger BioSig’s precise outcomes to vary from these contained in forward-looking statements, see Biosig’s filings with the Securities and Trade Fee (“SEC”), together with the part titled “Danger Components” in BioSig’s Quarterly Report on Kind 10-Q, filed with the SEC on November 14, 2023. Traders and safety holders are urged to learn these paperwork freed from cost on the SEC’s web site at http://www.sec.gov. The Firm assumes no obligation to publicly replace or revise its forward-looking statements because of new data, future occasions or in any other case, besides as required by legislation.
1 Cardiac Ablation Market. (2022, December). International Market Insights. https://www.gminsights.com/industry-analysis/cardiac-ablation
The publish BioSig Engages Consulting Agency for Enterprise Mannequin Methods – TipRanks Monetary Weblog appeared first on DailyBusiness.